FATE compared with RGNX: revenue, margins and what each company keeps, and the suppliers and customers both name

FATEFate Therapeutics Inc

Mkt capRevenueRevenue

RGNXRegenxbio Inc.

Mkt capRevenueRevenue

Compare

FATEFate Therapeutics Inc

RGNXRegenxbio Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

FATE: latest quarter is a loss; flow not drawable. RGNX: latest quarter not drawable.Method ›

Price

rebased to 0%

FATE, solidRGNX, dashed

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only FATE 8

—Baylor College of Medicineunlistedsupplier

—Dana Farber Cancer Instituteunlistedsupplier

—Memorial Sloan Kettering Cancer Centerunlistedsupplier

—The Scripps Research Instituteunlistedsupplier

4 more · FATE chain ›

Shared 0

No shared counterparties.

Only RGNX 17

ABBVAbbVie Global Enterprises Ltd. (AbbVie)customer

RAREUltragenyx Pharmaceuticalcustomer

GSKGlaxoSmithKline LLC (GSK)supplier

NVSNovartis Gene Therapies, Inc. (formerly AveXis, Inc.) (Novartis Gene Therapies)

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

customer

13 more · RGNX chain ›

FATEFate Therapeutics Inc

2.08▼−4.16%· post 2.08

Mkt cap$249.2MRevenue$2MQ2 FY26Revenue$7MFY25

RGNXRegenxbio Inc.

7.20▼−2.83%· post 7.20

ClosedOct 30 '26

Mkt cap$475.3MRevenue$108MQ2 FY26Revenue$170MFY25

Compare

ClosedOct 30 '26

FATEFate Therapeutics Inc

RGNXRegenxbio Inc.

2.08▼−4.16%post 2.08

Price

7.20▼−2.83%post 7.20

$249.2M

Mkt cap

$475.3M

Q2 FY26$2M

Revenue

$108MQ2 FY26

FY25$7M

Revenue

$170MFY25

FATE2.08▼−4.16%vsRGNX7.20▼−2.83%ClosedOct 30 '26